A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
The FDA launched two pilots to boost domestic manufacturing: PreCheck selected seven companies for earlier engagement, and a CVM pilot prioritizes animal drug applications with US-made ingredients.
Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
New AI tools predict diabetic kidney disease from retinal images, flag hemodialysis patients at hospitalization risk, and advance lupus nephritis care. Findings were presented at ARVO 2026 and published in NEJM Catalyst, The Lancet, and the International Journal of Molecular Sciences.
Novartis finalized a seventh new US facility as part of a $23 billion expansion. The new API site in Morrisville, North Carolina, supports end-to-end US manufacturing across multiple therapy platforms.
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
The U.S. pharmaceutical cold chain is under pressure as growth in mRNA, CAR-T and precision biologics outpaces temporary storage capacity. Annual losses near $35 billion are attributed to cold-chain failures.
Needle-free allergy therapy is forecast to expand through 2035 as self-administered options gain share. House dust mite allergy treatment is projected to grow from $3.18 billion in 2025 to $8.75 billion by 2033.
